MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the appointment Stephen Moore as General Counsel.
“We are very pleased to welcome Stephen to the Personalis team. He has an impressive track record with more than 20 years of in-house legal experience at advanced genomics companies,” said John West, President and Chief Executive Officer of Personalis. “This expertise will provide critical support as we advance Personalis.”
Mr. Moore joins Personalis after a decade at Pacific Biosciences (NASDAQ: PACB), where he served as General Counsel. Prior to Pacific Biosciences, Mr. Moore was General Counsel at Navigenics, a consumer genomics company that was later acquired by Life Technologies (now part of Thermo Fisher Scientific). Prior to Navigenics, he worked for over eight years at DNA microarray pioneer Affymetrix (which was also later acquired by Thermo Fisher Scientific), where he was most recently an Associate General Counsel. Mr. Moore holds a Bachelor of Arts degree in Political Science from San Jose State University, and a law degree from the University of California, Davis.
“I am pleased to join the Personalis team at this important time for the company,” said Mr. Moore. “After many years working at leading genomics tool and service providers with a shared vision that providing increasingly more comprehensive genomic information is critical to advancing our understanding of biological processes, I am enthusiastic to take part in the large-scale application of that vision to human health as Personalis grows its commercial operations and seeks to expand its market presence in immuno-oncology and potentially other disease areas, and in population-sized genome sequencing projects such as the VA MVP.”
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis ImmunoID NeXT Platform™ is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
This press release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding the potential advancement of or growth opportunities for Personalis’ business, expansion of Personalis’ market presence in immuno-oncology, the company’ services for the VA Million Veterans Program or other large-scale population sequencing projects, and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis’ filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Forms 10-K and 10-Q and subsequent filings and in the documents incorporated by reference therein, all of which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.